厄贝沙坦联合卡维地洛治疗慢性心衰的疗效观察

目的研究厄贝沙坦与卡维地洛联合应用在慢性心衰患者中的疗效。方法90例慢性心衰患者，随机分成厄贝沙坦＋卡维地洛组（实验组，45例）、卡托普利＋倍他乐克组（对照组，45例）。治疗前、治疗3个月后通过彩色多普勒超声心动图来评价其心功能情况，检测指标包括左室射血分数（LVEF）、左室收缩末期内径（LVESD）、左室舒张末期内径（LVEDD），血清BNP及6min步行实验，并进行比较。结果二组患者治疗后各项指标均有不同程度改善，实验组各指标包括LVEDD、LVESD、LVEF、BNP改善更为明显（52．8±3．4）VS（57．4±3．7），P=0．034；（41．3±2．7）vs（46．6±3．9），P=0．021；（42．3±3．4）VS（30．6±3．8），P=0．014；（463．8±56．34）VS（508．3±52．74），P=0．017，特别是患者6min步行实验结果（491．5±6．2VS415．4±5．5，P=0．008]。结论厄贝沙坦联合卡维地洛治疗更能改善慢性心衰患者心功能。

Effectiveness of irbesartan combined with carvedilol in patients with chronic heart failure

Objective To explore the effectiveness of Irbesartan combine with Carvedilol in patients with chronic heart failure （CHF）. Methods Ninety consecutive patients with CHF were divided into two .groups ： experimental group （ treatment with irbesartan and carvedilol, n = 45 ） and control group （ treatment with captopril and Metoprolol, n = 45） randomly. The parameters of LVEDD, LVESD, LVEF, BNP and 6 minutes walk test were compared between before and after 3 months treatment. Results All the parameters were im- proved after 3 months treatment either experimental group or control group. However, the change of LVEDV, LVESV, LVEF, BNP and 6 minutes walk test were more significantly in experimental group （52. 8 ±3. 4） vs （57. 4 ±3. 7）, P =0. 034; （41.3 ±2. 7） vs （46. 6 ±3. 9）, P =0. 021 ; （42. 3 ±3.4） vs （30. 6 ±3. 8）, P = 0. 014; （463.8 ±56. 34） vs （508.3 ±52. 74）, P =0. 017; （491.5 ±6. 2） vs （415.4 ±5. 5）, P =0.008]. Conclusion Treatment with Irbesartan combine with Carvedilol will more effectiveness in patients with CHF.